Search

Displaying results 3761 - 3770 of 5898 in total
  1. Drug

    Polydatin

    go.drugbank.com/drugs/DB11263
    Approved

    It is shown to mediate a cytotoxic action on colorectal cancer cells by inducing cell arrest and apoptosis [A27229].

    Synonyms: resveratrol-3-O-b-mono-D-glucoside, Resveratrol 3-O-beta-glucopyranoside
  2. Drug

    Hydrogenated soybean oil

    go.drugbank.com/drugs/DB11302
    Approved

    According to the FDA, hydrogenated soybean oil is generally recognized as safe (GRAS) food substance.

  3. Drug

    Malacidin B

    go.drugbank.com/drugs/DB14052
    Experimental

    While structurally similar to other macrocycle drugs like [DB00080] and [DB06087], Malacidin B appears to act via its own distinct mechanism.

  4. Drug

    Malacidin A

    go.drugbank.com/drugs/DB14051
    Experimental

    While structurally similar to other macrocycle drugs like [DB00080] and [DB06087], Malacidin A appears to act via its own distinct mechanism.

  5. Drug

    Faropenem medoxomil

    go.drugbank.com/drugs/DB05659
    Investigational

    The prodrug form of faropenem offers dramatically improved oral bioavailability and leads to higher systemic concentrations of the drug. … Faropenem medoxomil is a broad-spectrum antibiotic that is highly resistant to beta-lactamase degradation. It is being developed jointly by Replidyne, Inc. and Forest Laboratories, Inc.

  6. Drug

    Pantethine

    go.drugbank.com/drugs/DB11190
    Approved

    It consists of two molecules of pantetheine that form a dimer via disufide linkages, and acts as an intermediate in the production of Coenzyme A.

  7. Drug

    Ketamine

    go.drugbank.com/drugs/DB01221
    ApprovedInvestigationalVet approved

    It started being used for veterinary purposes in Belgium and in 1964 was proven that compared to PCP, it produced minor hallucinogenic effects and shorter psychotomimetic effects.

    Synonyms: 2-(o-chlorophenyl)-2-(methylamino)-cyclohexanoneProducts: NARKETAN 10% W/V INJECTABLE
  8. Drug

    SYNB1020

    go.drugbank.com/drugs/DB17667
    Investigational

    discontinued further development of SYNB1020 to treat hyperammonemia due to a lack of evidence of ammonia-lowering activities by SYNB1020 in a Phase 1b/2a study. … It was initially designed to convert ammonia to L-arginine [A258838] and granted orphan designation by the FDA for the treatment of urea cycle disorders in August 2016;[L45988] however, the manufacturer

  9. Drug

    Axitinib

    go.drugbank.com/drugs/DB06626
    ApprovedInvestigational

    It is reported to exhibit potency that is 50-450 times higher than that of the first generation VEGFR inhibitors.[L6676] Axitinib is an indazole derivative.

  10. Drug

    Briakinumab

    go.drugbank.com/drugs/DB05459
    Investigational

    Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and other autoimmune and inflammatory disorders. … It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha.